Titre
Fractionated Stereotactic Radiation Therapy for Pituitary Adenomas: An alternative escalating protocol of hypofractionated stereotactic radiotherapy delivering 35Gy in 5 fractions.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Sumodhee, S.
Auteure/Auteur
Atallah, V.
Auteure/Auteur
Kinj, R.
Auteure/Auteur
Doyen, J.
Auteure/Auteur
L'Homel, B.
Auteure/Auteur
Gillon, P.
Auteure/Auteur
Paquis, P.
Auteure/Auteur
Almairac, F.
Auteure/Auteur
Hieronimus, S.
Auteure/Auteur
Schiappa, R.
Auteure/Auteur
Sadoul, J.L.
Auteure/Auteur
Sumodhee, D.
Auteure/Auteur
Pontikos, N.
Auteure/Auteur
Richier, Q.
Auteure/Auteur
Hannoun-Levi, J.M.
Auteure/Auteur
Scouarnec, C.
Auteure/Auteur
Chevalier, N.
Auteure/Auteur
Bondiau, P.Y.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
1769-6658
Statut éditorial
Publié
Date de publication
2022-06
Volume
26
Numéro
4
Première page
557
Dernière page/numéro d’article
562
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Résumé
Evaluate efficacy and toxicity of hypofractionated stereotactic radiotherapy (HSRT) for patients treated for pituitary adenoma (PA) with an alternative HSRT escalating protocol delivering 35Gy in 5 fractions.
From June 2007 to March 2017, 29 patients with pituitary adenoma were treated in Antoine Lacassagne Cancer Centre with an alternative HSRT protocol. Prescribed dose was 35Gy in 5 fractions of 7Gy. Radiographic responses were assessed by annual MRI. Hormone blood samples were evaluated each year after HSRT.
A total of 29 patients aged between 23 and 86 years (median 54 years) were included. Twelve patients received HSRT for recurrent cases and 12 received postoperative adjuvant HSRT, 5 patients did not have surgery. After a median follow-up period of 47 months local control rate was 96%. One patient presented an out-field tumor regrowth 73 months after HSRT. The majority of PA were endocrine-active (18 patients, 62%). After HSRT, 8 patients (44%) presented complete response on initial secretion, 4 patients (23%) presented partial response on initial secretion. Four patients (14%) presented grade 2 or more acute radiation toxicities. One grade 4 visual disorder was observed for one patient.
HSRT delivering 35Gy in 5 fractions represents a feasible treatment and shows promising results to reduce hormonal overproduction and to improve local control in PA.
From June 2007 to March 2017, 29 patients with pituitary adenoma were treated in Antoine Lacassagne Cancer Centre with an alternative HSRT protocol. Prescribed dose was 35Gy in 5 fractions of 7Gy. Radiographic responses were assessed by annual MRI. Hormone blood samples were evaluated each year after HSRT.
A total of 29 patients aged between 23 and 86 years (median 54 years) were included. Twelve patients received HSRT for recurrent cases and 12 received postoperative adjuvant HSRT, 5 patients did not have surgery. After a median follow-up period of 47 months local control rate was 96%. One patient presented an out-field tumor regrowth 73 months after HSRT. The majority of PA were endocrine-active (18 patients, 62%). After HSRT, 8 patients (44%) presented complete response on initial secretion, 4 patients (23%) presented partial response on initial secretion. Four patients (14%) presented grade 2 or more acute radiation toxicities. One grade 4 visual disorder was observed for one patient.
HSRT delivering 35Gy in 5 fractions represents a feasible treatment and shows promising results to reduce hormonal overproduction and to improve local control in PA.
Sujets
PID Serval
serval:BIB_8252BA6D37ED
PMID
Date de création
2021-12-10T16:56:08.896Z
Date de création dans IRIS
2025-05-21T00:05:46Z